Page URL:

Genetic testing programme for cancer risk launched

28 May 2013
Appeared in BioNews 706

A genetic testing programme that will look for nearly 100 cancer risk genes has been launched, in the hope that genetic tests will become routine for cancer patients across the UK.

The three-year programme will initially test those with breast and ovarian cancer in the Royal Marsden Hospital, UK. If patients are found to have mutations in genes linked to cancer predisposition, they may require more comprehensive treatment and frequent monitoring, and their relatives could also require genetic screening.

'It is very important to know if a mutation in a person's genetic blueprint has caused their cancer', said Professor Nazneen Rahman, lead investigator of the programme. 'Such people are often at risk of getting another cancer and may choose to have more comprehensive surgery, may need different medicines, or extra monitoring'.

'It also improves the information available for relatives about their own cancer risks. Sometimes a relative is found to also have an increased risk of cancer and screening or preventative measures can be employed. Just as frequently, testing provides the reassuring news that a relative is not at increased risk of cancer and does not need interventions'.

A single blood test will be used to examine 'cancer predisposition genes': 94 genes and 284 single nucleotide polymorphisms (SNPs) which are strongly linked to an increased risk of various cancers if mutated. The genes and SNPs included in the test will be constantly updated as new research accumulates.

One of the genes analysed by the test is BRCA1, mutations in which recently led actress Angelina Jolie to undergo a preventative double mastectomy, thus reducing her risk of breast cancer from 87 percent to less than five percent. However, in her article in the New York Times, she acknowledges that in the US, the cost of a genetic test for BRCA1/2 mutations is an obstacle for many. In the UK, genetic testing for cancer patients is requested only if doctors suspect that a patient has an inherited form of cancer.

The £2.7 million pilot study is part of the Mainstreaming Cancer Genetics project, and is a collaboration between the Institute of Cancer Research, the Wellcome Trust, and genetic sequencing company Illumina, who manufacture the blood test. They are aiming to develop the infrastructure needed to make the genetic test routinely available to all patients with cancer.

Professor Ted Bianco, acting director of the Wellcome Trust, said: 'There is much expectation about the promise of new technologies in genetics contributing to a sea-change in medicine and this programme is a significant step on the road to making that a reality'.

Cancer risk gene testing announced
BBC News |  20 May 2013
New model for genetic testing in cancer patients launched (press release)
Wellcome Trust |  20 May 2013
New scheme to routinely test patients for inherited cancer genes
Cancer Research UK |  21 May 2013
UK tries out new model for gene testing in cancer patients
Reuters |  20 May 2013
23 February 2015 - by Isobel Steer 
Within the first minute, it is already clear that genomic sequencing is something of a Pandora's Box; or, as AC Grayling calls it, 'a modern dilemma'...
26 August 2014 - by Dr Molly Godfrey 
The DNA sequencing company Illumina have announced collaborations with three major pharmaceutical companies - AstraZeneca, Sanofi and Johnson & Johnson - to develop a single test for several gene mutations in cancer...
7 October 2013 - by Ruth Retassie 
A London clinic has reported an increase in the number of requests for BRCA genetic testing and preventative mastectomies since Angelina Jolie's announcement last May that she had undergone a double mastectomy....
16 September 2013 - by Daniel Riddell 
Advances in DNA sequencing mean that high-throughput, routine genetic testing of people with cancer is now a realistic possibility...
9 September 2013 - by Alastair Kent and Nick Meade 
This week, the new policy of American health insurer, Cigna, that requires genetic counselling before access to BRCA genetic testing, will come into effect. Reaction to this announcement has been mixed. We thought it would be interesting to compare this new policy with how genetic testing for BRCA cancer risk is delivered in the UK....
20 May 2013 - by Dr James Heather 
The US medicines regulator, the Food and Drug Administration, has approved a genetic test to help doctors select suitable lung cancer patients to be treated with the drug erlotinib...
13 May 2013 - by Daryl Ramai 
A genetic test released in the USA claims to be able to score the aggressiveness of prostate cancer before medical intervention, helping men with the condition decide if and when to start receiving treatment....
7 May 2013 - by Suzanne Elvidge 
Genetic analysis of tumours provides the key to treating them effectively, according to two studies carried out by The Cancer Genome Atlas (TCGA)....
18 March 2013 - by Dr Nicola Davis 
A blood test is being developed that could help doctors monitor how breast cancer tumours respond to therapy...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.